Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-17T16:14:17.781Z Has data issue: false hasContentIssue false
  • English
  • Français

Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia

Published online by Cambridge University Press:  19 July 2023

Z. Mielczarek ,
B. Trędzbor  and
K. Krysta
Z. Mielczarek
Affiliation:
Students’ Scientific Association, Department of Rehabilitation Psychiatry
B. Trędzbor
Affiliation:
Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland
K. Krysta*
Affiliation:
Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative symptoms and cognitive functions. It is a medicine with a multi-receptor mechanism of action: it mainly blocks dopaminergic D2 and serotonergic 5-HT2A receptors. According to the Summary of Product Characteristics, adverse reactions such as leucopenia, neutropenia and anaemia were too rare to estimate their frequency.

Objectives

This study describes case of neutrocytopenia and leukocytopenia that are likely to be related to lurasidone and have resolved after discontinuation of this medicinal product. The aim of the article is to highlight the risk of using second-generation antipsychotics in patients and the occurence of blood cells disorders in particular neutrocytopenia.

Methods

An analysis of the medical history records were done to describe the case report.

Results

39-years-old patient treated psychiatrically for 18 years, initially for mood disorders, irritability, behavioural disorders. In 2014 she was diagnosed with paranoid schizophrenia, herlast psychiatric hospitalization took place in 2021. The patient had a history of neutrocytopenia and leukocytopenia. In December 2020, the patient was admitted to the psychiatric ward on account of active aggression against her mother. She was discharged in January 2021 with the recommendation to take paliperidone intramusculary. Due to incomplete remission of psychotic symptoms, the patient received 37 mg of lurasidone since August 2021. The blood count, which was ordered upon admission to the Department of Psychiatric Rehabilitation, showed moderate neutrocytopenia. After discontinuation of lurasidone and the recommended supplementation, the results gradually improved and finally reached the normal range.

Blood cells type23.09.2021 r.04.10.2021 r.14.10.2021 r.28.10.2021 r.10.11.2021 r.24.11.2021 r.08.12.2021 r.
Leukocytes2,45 x 10^3/μl2,73 x 10^3/μl2,39 x 10^3/μl2,66 x 10^3/μl2,79 x 10^3/μl4,09 x 10^3/μl4,03 x 10^3/μl
Erythrocytes4,26 x 10^3/μl4,31 x 10^3/μl4,48 x 10^3/μl4,06 x 10^3/μl4,08 x 10^3/μl4,39 x 10^3/μl4,22 x 10^3/μlb
Neutrocytes1,04 x 10^3/μl1,60 x 10^3/μl1,24 x 10^3/μl1,53 x 10^3/μl1,78 x 10^3/μl2,72 x 10^3/μl2,62 x 10^3/μl
Lymphocytes1,05 x 10^3/μl0,70 x 10^3/μl0,72 x 10^3/μl0,73 x 10^3/μl0,64 x 10^3/μl0,83 x 10^3/μl0,92 x 10^3/μl

Conclusions

This case report shows the need for regular monitoring of blood cells parameters in patients treated with second generation antipsychotics, as there is a risk of neutrocytopenia or even agranulocitosis. If there is an obvious correlation, the dose should be reduced or switched to another medicinal product if possible and blood counts should monitored further.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1065
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.